Gaoxiao Zhang1, Tao Zhang1, Ning Li1, Liangmiao Wu1, Jianbo Gu1,2, Cuimei Li2, Chen Zhao1, Wei Liu2, Luchen Shan1, Pei Yu1, Xifei Yang3, Yaohui Tang4, Guo-Yuan Yang4, Yuqiang Wang1, Yewei Sun1, Zaijun Zhang1. 1. Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, China. 2. Guangzhou Magpie Pharmaceuticals Co., LTD., Guangzhou, China. 3. Key Laboratory of Modern Toxicology of Shenzhen, Center for Disease Control and Prevention, Shenzhen, China. 4. Neuroscience and Neuroengineering Center, Med-X Research Institute and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.
Abstract
BACKGROUND AND PURPOSE: Neuronal regeneration from endogenous precursors is an attractive strategy for the treatment of ischaemic stroke. However, most stroke-generated newborn neurons die over time. Therefore, a drug that is both neuroprotective and pro-neurogenic may be beneficial after stroke. Here, we assessed the neurogenic and oligodendrogenic effects of tetramethylpyrazine nitrone (TBN), a neuroprotective drug candidate for stroke, in a rat model of ischaemic stroke. EXPERIMENTAL APPROACH: We used Sprague Dawley rats with middle cerebral artery occlusion (MCAO). TBN was administered by tail vein injection beginning at 3 h post ischaemia. Therapeutic effect of TBN was evaluated by neurological behaviour and cerebral infarction. Promotion of neurogenesis and oligodendrogenesis was determined by double immunofluorescent staining and Western blotting analyses. Primary cultures of cortical neurons were used to assess the effect of TBN on neuronal differentiation in vitro. KEY RESULTS: TBN reduced cerebral infarction, preserved and/or restored neurological function and promoted neurogenesis and oligodendrogenesis in rats after MCAO. In addition, TBN stimulated neuronal differentiation on primary culture of cortical neurons in vitro. Pro-neurogenic effects of TBN were attributed to its activation of the AKT/cAMP responsive element-binding protein through increasing brain-derived neurotrophic factor (BDNF) expression, as shown by the abolition of the effects of TBN by a specific inhibitor of BDNF receptor ANA-12 and by the PI3K inhibitor LY294002. CONCLUSION AND IMPLICATIONS: As TBN can simultaneously provide neuroprotection and pro-neurogenic effects, it may be a promising treatment for both acute phase neuroprotection and long-term functional recovery after ischaemic stroke.
BACKGROUND AND PURPOSE: Neuronal regeneration from endogenous precursors is an attractive strategy for the treatment of ischaemic stroke. However, most stroke-generated newborn neurons die over time. Therefore, a drug that is both neuroprotective and pro-neurogenic may be beneficial after stroke. Here, we assessed the neurogenic and oligodendrogenic effects of tetramethylpyrazine nitrone (TBN), a neuroprotective drug candidate for stroke, in a rat model of ischaemic stroke. EXPERIMENTAL APPROACH: We used Sprague Dawley rats with middle cerebral artery occlusion (MCAO). TBN was administered by tail vein injection beginning at 3 h post ischaemia. Therapeutic effect of TBN was evaluated by neurological behaviour and cerebral infarction. Promotion of neurogenesis and oligodendrogenesis was determined by double immunofluorescent staining and Western blotting analyses. Primary cultures of cortical neurons were used to assess the effect of TBN on neuronal differentiation in vitro. KEY RESULTS:TBN reduced cerebral infarction, preserved and/or restored neurological function and promoted neurogenesis and oligodendrogenesis in rats after MCAO. In addition, TBN stimulated neuronal differentiation on primary culture of cortical neurons in vitro. Pro-neurogenic effects of TBN were attributed to its activation of the AKT/cAMP responsive element-binding protein through increasing brain-derived neurotrophic factor (BDNF) expression, as shown by the abolition of the effects of TBN by a specific inhibitor of BDNF receptor ANA-12 and by the PI3K inhibitor LY294002. CONCLUSION AND IMPLICATIONS: As TBN can simultaneously provide neuroprotection and pro-neurogenic effects, it may be a promising treatment for both acute phase neuroprotection and long-term functional recovery after ischaemic stroke.
Authors: Andrew N Clarkson; Kim Parker; Michael Nilsson; F Rohan Walker; Emma K Gowing Journal: J Cereb Blood Flow Metab Date: 2015-03-11 Impact factor: 6.200
Authors: S J Mowla; S Pareek; H F Farhadi; K Petrecca; J P Fawcett; N G Seidah; S J Morris; W S Sossin; R A Murphy Journal: J Neurosci Date: 1999-03-15 Impact factor: 6.167
Authors: Sean C L Deoni; Evelyne Mercure; Anna Blasi; David Gasston; Alex Thomson; Mark Johnson; Steven C R Williams; Declan G M Murphy Journal: J Neurosci Date: 2011-01-12 Impact factor: 6.167
Authors: Zaijun Zhang; Gaoxiao Zhang; Yewei Sun; Samuel S W Szeto; Henry C H Law; Quan Quan; Guohui Li; Pei Yu; Eiketsu Sho; Michael K W Siu; Simon M Y Lee; Ivan K Chu; Yuqiang Wang Journal: Sci Rep Date: 2016-11-14 Impact factor: 4.379